Progesterone vaginal capsules
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Vaginal capsules of progesterone.
Drugs List
Therapeutic Indications
Uses
Luteal supplementation after embryo transfer during assisted reproduction
Supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.
Dosage
Adults
600mg daily, in three divided doses, from the day of embryo transfer until at least the 7th week of pregnancy and not later than the 12th week of pregnancy.
Administration
Insert deep into the vagina.
Contraindications
Breast cancer
Breastfeeding
Cerebrovascular haemorrhage
Female genital cancer
Missed abortion
Porphyria
Second trimester of pregnancy
Severe hepatic impairment
Third trimester of pregnancy
Thromboembolic disorder
Thrombophlebitis
Undiagnosed gynaecological haemorrhage
Precautions and Warnings
History of cholestasis of pregnancy
Contains soya or soya derivative
Usual treatment period is up to 12 weeks
Progesterone vaginal capsules should only be used during the first trimester of pregnancy.
Use of progesterone after the first trimester increases the risk of cholestasis of pregnancy.
Pregnancy and Lactation
Pregnancy
Utrogestan is considered safe and it is indicated during the first 12 weeks of pregnancy.
The manufacturer states that there has been no link between the use of natural progesterone in early pregnancy and effects on foetal development.
Lactation
Utrogestan is contraindicated during breastfeeding.
The manufacturer does not indicate use during breastfeeding. Utrogestan is present in human breast milk.
Side Effects
Breast discomfort
Pruritus
Vaginal discharge
Vaginal discomfort
Vaginal haemorrhage
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: May 2019
Reference Sources
Summary of product characteristics: Utrogestan Vaginal 200mg capsules. Besins Healthcare (UK) Ltd. Revised April 2019.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 20 May 2019
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.